Cidel Asset Management Inc. lowered its holdings in Johnson & Johnson (NYSE:JNJ – Get Rating) by 14.6% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 154,770 shares of the company’s stock after selling 26,418 shares during the quarter. Cidel Asset Management Inc.’s holdings in Johnson & Johnson were worth $25,283,000 as of its most recent filing with the SEC.

→ The Next Big Crisis Is Here (From Porter & Company)

A number of other hedge funds and other institutional investors also recently bought and sold shares of JNJ. Morton Brown Family Wealth LLC increased its position in shares of Johnson & Johnson by 78.0% in the second quarter. Morton Brown Family Wealth LLC 8 now owns 17 of the company’s stock valued at $32,000 after buying an additional 78 shares in the last quarter. Goodman Advisory Group LLC purchased a new position in shares of Johnson & Johnson in the second quarter valued at $39,000. First Bank & Trust increased in its position Johnson & Johnson by 69.6% in the second quarter. First Bank & Trust now owns 380 shares of the company’s stock valued at $67,000 after buying an additional 156 shares in the last quarter. Heritage Wealth Management LLC purchased a new position of son & John in shares Johnson in the second quarter valued at $84,000. Finally, Timber Creek Capital Management LLC increased its position in shares of Johnson & Johnson by 225.0% in the third quarter r. Timber Creek Capital Management LLC now owns 650 shares of the company’s stock valued at $106,000 after buying an additional 450 shares in the last quarter. Institutional investors and hedge funds own 67.94% of the company’s stock.

Johnson & Johnson Stock Down 0.4%

JNJ opened at $168.23 on Monday. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.43 and a quick ratio of 1.18. The stock has a market capitalization of $439.83 billion, a price-to-earnings ratio of 24.96, a price-to-earnings-growth ratio of 2.89 and a beta of 0.56. The business has a 50-day moving average of $175.63 and a two-hundred day moving average of $170.93. Johnson & Johnson has a 12 month low of $155.72 and a 12 month high of $186.69.

Johnson & Johnson (NYSE:JNJ – Get Rating) last released its quarterly earnings data on Tuesday, January 24th. The company reported $2.35 earnings per share for the quarter, beating the consensus estimate of $2.22 by $0.13. The business had revenue1 of $23.7 for the quarter, compared to analyst estimates of $23.90 billion. Johnson & Johnson had a return on equity of 35.94% and a net margin of 18.90%. The company’s revenue was down 4.4% compared to the same quarter last year. During the same period In the previous year, the company posted $2.13 EPS. On average, research analysts expect that Johnson & Johnson will post 10.51 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 7th. Stockholders of record on Tuesday, February 21st will be paid a $1.13 dividend. This represents a $4.52 annualized dividend and a dividend yield of The 2.69%. -dividend date is Friday, February 17th. Johnson & Johnson’s dividend payout ratio is currently 67.06%.

Insider Activity

In related news, VP Thibaut Mongon sold 35,246 shares of the business’s stock in a transaction that occurred on Friday, November 4th. The stock was sold at an average price of $171.18, for a total transaction of $6,033,410.28. now directly owns 40,133 shares of the company’s stock, valued at approximately $6,869,966.94. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Johnson & Johnson stock in a transaction that occurred on Friday, November 4th. The stock was sold at an average price of $171.18, for a total transaction of $6,033,410.28. Following the sale, the vice president now directly owns 40,133 shares in the valued company, at approximately $6,869,966.94. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC web site. Also, CFO Joseph J. Wolk sold 14,781 shares of Johnson & Johnson stock in a transaction that occurred on Tuesday, December 13th. The stock was sold at an average price of $179.60, for a total value of $2,654,667.60. Following the sale, the chief financial officer now owns 35,812 shares in the company, valued at $6,431,835.20. The disclosure for this sale can be found here. Insiders have sold 233,611 shares of company stock valued at $40,960,735 in the last three months. company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on JNJ shares. StockNews.com started coverage on Johnson & Johnson in a research report on Wednesday, October 12th. They issued a “strong-buy” rating for the company. Raymond James dropped their price objective on Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating for the company in a research report on Wednesday, October 19th. Barclays started coverage on Johnson & Johnson in a research report on Monday, October 17th. They set an ” equal weight” rating and a $175.00 price objective for the company. Morgan Stanley lifted their price objective on Johnson & Johnson from $176.00 to $180.00 and gave the stock an “equal weight” rating in a research report on Wednesday, January 25th. Finally, SVB Leerink dropped their price objective on Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating for the company in a research report on Friday, January 20th. Seven research analysts have rated the stock wit h a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $182.75.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or out comments about this story [email protected].

Before you consider Johnson & Johnson, you’ll want to hear this.

MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before market the broader on… and Johnson & Johnson wasn’t on the list.

While Johnson & Johnson currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here